Insider Transactions in Q3 2023 at Cytom X Therapeutics, Inc. (CTMX)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 22
2023
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,119
-5.12%
|
$4,119
$1.3 P/Share
|
|
Sep 22
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,119
-2.71%
|
$4,119
$1.3 P/Share
|
|
Sep 22
2023
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
5,486
-6.37%
|
$5,486
$1.3 P/Share
|
|
Sep 22
2023
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
14,601
-3.28%
|
$14,601
$1.3 P/Share
|
|
Sep 20
2023
|
Jeffrey B Landau Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+12.26%
|
-
|
|
Sep 20
2023
|
Marcia Belvin SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+6.89%
|
-
|
|
Sep 20
2023
|
Lloyd A Rowland General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+14.84%
|
-
|
|
Sep 20
2023
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+8.24%
|
-
|